A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
BackgroundCompared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of the research was to evaluate the cost-effectiveness...
Kaydedildi:
Asıl Yazarlar: | , , , , , , , , , |
---|---|
Materyal Türü: | Kitap |
Baskı/Yayın Bilgisi: |
Frontiers Media S.A.,
2020-05-01T00:00:00Z.
|
Konular: | |
Online Erişim: | Connect to this object online. |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
Yer Numarası: |
A1234.567 |
---|---|
Kopya Bilgisi 1 | Kütüphanede |